Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients

M. Wawruch, M. Petrova, D. Celovska, SD. Alfian, T. Tesar, J. Murin, M. Trnka, T. Paduch, E. Aarnio

. 2024 ; 15 (-) : 1464689. [pub] 20241218

Status not-indexed Language English Country Switzerland

Document type Journal Article

INTRODUCTION: The benefit of secondary prevention in hypertensive patients with peripheral arterial disease (PAD) is based on continual simultaneous taking of statins, antiplatelet agents and antihypertensive agents, preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Our study was aimed at a) the analysis of the extent of non-persistence with multiple medication classes, and b) identifying factors associated with the likelihood of non-persistence. METHODS: In our cohort study, 3,401 hypertensive patients (1,853 females and 1,548 males) aged ≥65 years treated simultaneously with statins, antiplatelet agents and ACEIs/ARBs and in whom PAD was newly diagnosed during 2012 were analysed. A patient was classified as non-persistent when he/she was non-persistent with at least one of the three analysed medication classes. The most important characteristics associated with the probability of non-persistence were identified using the Cox regression. RESULTS: At the end of the follow-up period (mean length 1.8 years), 1,869 (55.0%) patients (including 1,090 females and 779 males) were classified as non-persistent. In the whole study cohort, factors associated with non-persistence were female sex, atrial fibrillation, and being a new user of at least one of the analysed medication classes; in males, they were university education, atrial fibrillation, and epilepsy, and, in females, being a new user. CONCLUSION: Identification of sex differences in factors associated with non-persistence makes it possible to determine the groups of patients in whom special attention should be paid to improving their persistence with a combination of medicines in order to ensure successful secondary prevention of PAD.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008806
003      
CZ-PrNML
005      
20250422095640.0
007      
ta
008      
250408e20241218sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2024.1464689 $2 doi
035    __
$a (PubMed)39744138
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Wawruch, Martin $u Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
245    10
$a Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients / $c M. Wawruch, M. Petrova, D. Celovska, SD. Alfian, T. Tesar, J. Murin, M. Trnka, T. Paduch, E. Aarnio
520    9_
$a INTRODUCTION: The benefit of secondary prevention in hypertensive patients with peripheral arterial disease (PAD) is based on continual simultaneous taking of statins, antiplatelet agents and antihypertensive agents, preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Our study was aimed at a) the analysis of the extent of non-persistence with multiple medication classes, and b) identifying factors associated with the likelihood of non-persistence. METHODS: In our cohort study, 3,401 hypertensive patients (1,853 females and 1,548 males) aged ≥65 years treated simultaneously with statins, antiplatelet agents and ACEIs/ARBs and in whom PAD was newly diagnosed during 2012 were analysed. A patient was classified as non-persistent when he/she was non-persistent with at least one of the three analysed medication classes. The most important characteristics associated with the probability of non-persistence were identified using the Cox regression. RESULTS: At the end of the follow-up period (mean length 1.8 years), 1,869 (55.0%) patients (including 1,090 females and 779 males) were classified as non-persistent. In the whole study cohort, factors associated with non-persistence were female sex, atrial fibrillation, and being a new user of at least one of the analysed medication classes; in males, they were university education, atrial fibrillation, and epilepsy, and, in females, being a new user. CONCLUSION: Identification of sex differences in factors associated with non-persistence makes it possible to determine the groups of patients in whom special attention should be paid to improving their persistence with a combination of medicines in order to ensure successful secondary prevention of PAD.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Petrova, Miriam $u Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Celovska, Denisa $u Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Alfian, Sofa D $u Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia $u Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia
700    1_
$a Tesar, Tomas $u Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia
700    1_
$a Murin, Jan $u Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Trnka, Michal $u Institute of Medical Physics and Biophysics, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Paduch, Tomas $u 2nd Department of Surgery, Center for Vascular Disease, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Aarnio, Emma $u School of Pharmacy, University of Eastern Finland, Kuopio, Finland
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 15 (20241218), s. 1464689
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39744138 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095641 $b ABA008
999    __
$a ok $b bmc $g 2306492 $s 1245881
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 15 $c - $d 1464689 $e 20241218 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20250408

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...